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Abstract
Background: Trypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease.
Until 2009, available treatments for 2nd stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic,
and insufficiently effective in certain areas (melarsoprol). Recently, nifurtimox-eflornithine combination therapy (NECT)
demonstrated good safety and efficacy in a randomised controlled trial (RCT) and was added to the World Health
Organisation (WHO) essential medicines list (EML). Documentation of its safety profile in field conditions will support its
wider use.
Methodology: In a multicentre, open label, single arm, phase IIIb study of the use of NECT for 2nd stage T.b. gambiense HAT,
all patients admitted to the trial centres who fulfilled inclusion criteria were treated with NECT. The primary outcome was
the proportion of patients discharged alive from hospital. Safety was further assessed based on treatment emergent adverse
events (AEs) occurring during hospitalisation.
Principal Findings: 629 patients were treated in six HAT treatment facilities in the Democratic Republic of the Congo (DRC),
including 100 children under 12, 14 pregnant and 33 breastfeeding women. The proportion of patients discharged alive
after treatment completion was 98.4% (619/629; 95%CI [97.1%; 99.1%]). Of the 10 patients who died during hospitalisation,
8 presented in a bad or very bad health condition at baseline; one death was assessed as unlikely related to treatment. No
major or unexpected safety concerns arose in any patient group. Most common AEs were gastro-intestinal (61%), general
(46%), nervous system (mostly central; 34%) and metabolic disorders (26%). The overall safety profile was similar to
previously published findings.
Conclusions/Significance: In field conditions and in a wider population, including children, NECT displayed a similar
tolerability profile to that described in more stringent clinical trial conditions. The in-hospital safety was comparable to
published results, and long term efficacy will be confirmed after 24 months follow-up.
Registration: The trial is registered at ClinicalTrials.gov, number NCT00906880.
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Introduction
Human African trypanosomiasis (HAT) is one of the most
neglected tropical diseases (NTDs), suffering from a lack of optimal
control tools and insufficient research efforts. It affects people in
sub-Saharan Africa who often live in remote and/or insecure
areas, with limited access to health care [1]. Owing to past and
ongoing surveillance and control efforts of the National Control
programmes from the affected countries supported mainly by
WHO (World Health Organisation), BTC (Belgian Development
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Agency) and MSF (Me´decins Sans Frontie`res), less than 10’000
HAT patients are currently reported each year [2]. However,
funding to keep up an adequate level of control activities is
nowadays increasingly difficult to obtain. Moreover, in almost all
cases, HAT is fatal if untreated. T.b. gambiense accounts for 95% of
currently reported HAT cases. The disease progresses from 1st
stage (infecting blood and lymph) to 2nd stage (affecting the central
nervous system), which ultimately leads to severe sleep distur-
bances, other neurological and psychiatric disorders, coma and
eventually death.
Until 2009, treatment for the 2nd stage of T.b. gambiense HAT
was limited to melarsoprol, an arsenic derivative, or eflornithine.
Treatment with melarsoprol is associated with high toxicity, is
sometimes fatal (mean 9.4% (range 2.7–34%) [3]), and displays
high rates of failure in several geographic areas [4,5,6,7,8,9].
Although safer and more effective [4], eflornithine monotherapy
comes with burdensome treatment administration requiring 56
slow infusions administered every 6 hours over 2 weeks that are
difficult to implement outside well-staffed hospital settings.
A new treatment alternative, nifurtimox-eflornithine combina-
tion therapy (NECT), was added to the World Health Organisa-
tion’s Essential Medicines List (WHO EML) in 2009 for the
treatment of 2nd stage T.b. gambiense HAT [10], based on its
efficacy and safety profile observed in a randomised controlled
trial conducted in a well-defined study population [11]. NECT is
easier to administer and requires fewer hospital resources than
eflornithine monotherapy, with only 14 slow infusions adminis-
tered every 12 hours for 1 week, with a concurrent 10 days oral
treatment with nifurtimox. The needed quantity of eflornithine for
NECT (and consequently the drug production and transportation
cost) is 2 times lower than for the eflornithine monotherapy
regimen. NECT now stands as the preferred first-line treatment
for 2nd stage T.b. gambiense HAT. However, it is not yet the ideal
HAT treatment and to enable its wider use in remote rural
settings, financial and logistical barriers must be overcome, health
care staff must be well trained, and, importantly, the safety profile
under such conditions needs to be better known.
This study aimed to further document the clinical tolerability,
feasibility and effectiveness of treatment with NECT in field
conditions, i.e. with less stringent inclusion/exclusion criteria and
in a larger population including children, pregnant and breast-
feeding women and patients with a HAT treatment history.
Methods
Objectives
The primary objective was to assess the clinical response of
NECT for the treatment of 2nd stage T.b. gambiense HAT in field
conditions. Secondary objectives included assessing the incidence
and type of adverse events (AE), the feasibility of NECT
implementation by the health facilities and the effectiveness of
NECT at 24 months after treatment. Patient follow-up is still
ongoing at the time of publication, therefore the current analysis
deals with in-hospitalisation safety only.
Outcomes
The primary outcome was the proportion of patients discharged
alive from the hospital (treatment facility). This was directly
assessed by the site Investigators after treatment at the time of
discharge. Secondary outcomes were frequency, nature, severity
and relatedness of adverse events and adherence to treatment
(interruptions, cessations, dose deviations, length of hospitalisa-
tion).
Study design, settings and participants
This was a multicentre, open label, single arm, phase IIIb study
of the therapeutic use of NECT for treatment of 2nd stage T.b.
gambiense HAT in the Democratic Republic of the Congo (DRC).
The study took place in two of the most endemic provinces,
Bandundu and Kasai Oriental, at five HAT treatment facilities
operated by the national HAT control program (Programme
National de Lutte contre la Trypanosomiase Humaine Africaine,
PNLTHA): Bandundu, Dipumba, Katanda, Kwamouth and
Ngandajika and one treatment facility operated by the BDOM/
KIKWIT (Bureau Diocesain d’Oeuvres Me´dicales) and supervised
by the PNLTHA: General Hospital of Yasa Bonga.
All second stage HAT patients admitted to the treatment
facilities and routinely diagnosed according to the national
guidelines and who gave their Informed Consent for participation,
were included in the trial. At inclusion, special attention was given
to children and pregnant and breastfeeding women. It was under
the Investigator’s decision to include these sub-populations.
Exclusion criteria were inability to take oral medication and
impossibility to use a nasogastric tube, treatment failure after
previous NECT treatment or any other condition for which the
Investigator judged that another treatment was warranted. The
patients were hospitalised and treated with NECT and monitored
for adverse events. During the trial, an independent Data Safety
Monitoring Board (DSMB) reviewed the data for patient safety.
No interim analyses were done.
Intervention
Prior to NECT initiation, the patients received standard pre-
treatment (according to the facilities’ guidelines, usually antima-
larial, anthelminthic and antipyretic/analgesic medication). All
patients received NECT [11], the co-administration of nifurtimox
(oral 15 mg/kg/day, three times a day) for 10 days and
eflornithine (slow intravenous infusions, 400 mg/kg/day, twice a
day) for 7 days.
All patients, including the children and offspring of pregnant or
breastfeeding women, were monitored during treatment and
Author Summary
Sleeping sickness is a neglected tropical disease affecting
people in Sub-Saharan Africa, most of them in poor, rural
settings. If not treated, the disease usually progresses into
a serious stage affecting the central nervous system,
causing severe sleep disturbances, as well as other
neurological and psychiatric disorders, coma, and death.
Until recently, the only ways to treat 2nd stage gambiense
sleeping sickness involved drugs that were either toxic
(such as the arsenic derivative melarsoprol) or difficult to
administer in resource-constrained settings (e.g. eflor-
nithine). A new treatment, nifurtimox-eflornithine combi-
nation therapy (NECT), was developed and tested in
clinical trials, and is now recommended as the treatment
of choice for 2nd stage sleeping sickness. NECT is easier to
administer than eflornithine, but more information needs
to be gathered for its use in the field: logistical barriers
must be overcome, health care staff must be well trained,
and, importantly, the safety profile of the treatment in real-
life conditions needs to be better evaluated. We report
here the results of a study designed to gain better
understanding of the clinical tolerability, feasibility and
effectiveness of NECT in field conditions, and to gather
data on its use in specific populations, such as children and
pregnant women.
NECT for HAT Implemented in Field Conditions
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followed-up for safety issues. Patients underwent daily evaluations,
including vital signs, physical examination, adverse event moni-
toring, and recording of concomitant medications throughout the
admission and treatment period, as well as at the end of treatment,
just before patients were discharged from hospital.
The severity of the treatment emergent adverse events was
graded by the Investigator, according to the Common Toxicity
Criteria for adverse events (CTCAE, v03 [12] from grades 1 to 5
as mild, moderate, severe, life-threatening and death) and related
to the treatment according to the Investigator’s analysis. Treat-
ment emergent adverse events were evaluated as being probably,
possibly or not related to the study drugs.
Follow-up assessment visits were scheduled 6, 12, 18 and 24
months after the end of the treatment. Twenty-four months after
end of treatment, patients will be assessed for the final effectiveness
of treatment; these results will be reported later.
Sample size
According to available literature [4,11,13,14], the proportion of
patients discharged alive from hospital (P1) was expected to be
equal or superior to 98%. The proportion of patients discharged
alive from hospital (under the null hypothesis) was assumed to be
equal to P0 = 96%, which corresponds to the average of
proportions obtained in previous studies on eflornithine.
The sample size was calculated according to a confidence
interval approach with a precision of 2%. According to Fleiss’
method [15], a sample size of 620 achieved 80% power to detect a
difference (P1-P0) of 2% using a two-sided binomial test. The target
significance level was 5%. Sample size was performed using PASS
2008 [16].
Statistical analysis
The main analysis set was the safety population, which included
all subjects who received at least one dose of study drug. For this
trial design, safety and ITT (intention to treat) populations are the
same. As the percentage of patients who had protocol deviations
was very small (0.7%), the per-protocol population was not
analysed.
All statistical evaluations were descriptive, as the aim of the
study was to further document NECT implemented in field
conditions and the trial was open-label and uncontrolled. Means,
standard deviations and number of patients were provided for
continuous variables, as well as frequency distributions for binary
and categorical variables. An exact Wilson 95% confidence
interval was calculated for the primary outcome. Statistical
analyses were performed using the SAS software version 9.1
(SAS Institute, Cary, NC).
All data were captured at the participating treatment facility on
patient case report forms (CRFs). Data were double-entered and
discrepancies reviewed and corrected against the hard copy CRF.
Adverse events were coded with the MedDRA dictionary
(version 11.0 [17]) and concomitant treatments with the WHO-
Drug dictionary [18].
Ethics
This research was conducted in full accordance with the ethical
principles for medical research involving human subjects, as
expressed in the Declaration of Helsinki and following amend-
ments. Eligible patients were asked to meet the study Investigator
or his delegate, who explained the study protocol in detail
according to the patient information sheet, and requested written
consent from the patient or, in case of minors, severely ill or
mentally impaired patients unable to fully consent, from her/his
parent(s)/guardian(s). Whenever possible (depending on age and
level of understanding), the children received the information and
their assent was obtained. Two Ethics Committees approved the
study protocol: the Ethics Committee of both cantons of Basel
(EKBB, Basel, Switzerland; 26 February, 2009) and the local
Ethics Committee in the DRC (Comite d’Ethique sur la
Trypanosomiase Humaine Africaine, Kinshasa, Democratic Re-
public of the Congo, 7 May 2009). All interventions (including
follow-up visits) were free of charge to the patients.
Results
The total enrolment period lasted 13 months and took place
between May 2009 and May 2010 in six HAT treatment facilities
of the DRC. One facility (Yasa Bonga) recruited patients only
between November 2009 and May 2010. Here, we report the in-
hospitalisation safety of 629 2nd stage HAT patients treated with
NECT.
Study population - participant flow
Patients who reported passively or were sent by the mobile
teams to the HAT treatment facilities were screened and
diagnosed for HAT. 726 patients were diagnosed as HAT cases,
of them, 680 were classified in stage 2 and potentially eligible for
participation, 49 were excluded by the Investigators or failed to
show up for treatment, 1 refused and 630 gave their informed
consent. One patient died prior to receiving any medication and
was not included in the analysis. In total, 629 patients were treated
with NECT at the HAT treatment facilities. Reasons for non-
inclusion and the patient flow are detailed in Figure 1.
Baseline
The demographic, diagnostic and clinical characteristics varied
between the treatment facilities (Table 1). About 16% of the
patients were children below 12 years of age. Katanda had the
highest (22%) rate of children admitted and Bandundu (9%) the
lowest. The overall ratio of males to females was 1.3 (range 0.9 to
2.0). Amongst the patients, there were 33 (5%) breastfeeding
women, 14 (2%) pregnant women and 135 (22%) patients with
HAT treatment history (range 3% to 39%). Of patients with a
HAT history, two thirds were considered true relapses (84/135)
who were treated for HAT within 2 years prior admission to the
current treatment (Table 1). There were 188 (30%) malnourished
patients (172 (33%) adults and 16 (16%) children aged below 12
years,; based on age specific underweight classification of
anthropometric data according to WHO [19,20]). However, the
extent of malnutrition amongst the study population varied
between the facilities, with Dipumba reporting the lowest (15%)
and Bandundu and Yasa Bonga the highest proportion (40%) of
undernourished patients admitted.
All patients were diagnosed as stage 2 HAT patients with .5
leucocytes per ml CSF (cerebro-spinal fluid), of those, 89% (558/
629) were parasitologically confirmed and 11% (71/629) based on
their raised WBC (white blood cell) levels in CSF and clinical signs.
The latter presented either positive serology (7%, 44/629) or had
already a HAT history (4%, 27/629, data not shown). The clinical
and diagnostic findings differed slightly between sites.
Common disease symptoms by frequency of occurrence were
sleeping disorders (nocturnal insomnia and/or diurnal somno-
lence), headache, asthenia, fever, pruritus and weight loss, each
affecting more than half of all patients (Table 1).
Treatment and adherence to treatment
All patients were hospitalised for the entire treatment period.
Ninety-nine percent (621/629) and 94% (590/629) of the patients
NECT for HAT Implemented in Field Conditions
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received the complete eflornithine and nifurtimox doses, respec-
tively (as per protocol 14 intravenous doses of eflornithine and 30
oral doses of nifurtimox). Minor divergences occurred in the
timing of drug administration or by administration of additional
doses of nifurtimox (at the end of treatment) and/or in case of
vomiting within the first 30 minutes after the intake. Major
treatment deviations were due to overdosing of more than 10% of
correct treatment (calculated based on body weight; 3 patients) or
to withdrawal by family (1 patient) or to treatment cessation after 1
dose due to intolerance (1 patient). The adherence to treatment
varied slightly between the facilities and also amongst the patient
groups - lowest adherence was in the pregnant women group
(nifurtimox 79% & eflornithine 93%) and in small children below
5 years of age (nifurtimox 89% & eflornithine 86%; Table 2).
Concomitant medication during NECT therapy was common:
93% (585/629) of patients received in median 4 additional
different drugs (range 1–14). All pregnant women (14/14) and
86% (30/35) of children below 5 years of age received
concomitant treatment.
The median length of hospitalisation was 16 days, and
measured from the day of admission to the day of discharge,
including days when pre-medication was given (Table 2). The
length of the hospitalisation stay was similar for all patient groups,
but varied between the facilities (12 days in Bandundu, 15 days in
Dipumba, 16 days in Katanda, Ngandajika & Kwamouth, and 20
days in Yasa Bonga) mainly due to differing routine practices at
the facilities (reduced pre-treatment days in Bandundu or
prolonged observation days in Yasa Bonga).
Figure 1. Flow diagram of the multicentre NECT trial for treatment of 2nd stage HAT. The diagram includes detailed information on
excluded patients.
doi:10.1371/journal.pntd.0001920.g001
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In-hospitalisation safety
98.4% (619/629) of patients were discharged alive
(95%CI= [97.1%; 99.1%], Table 2). All children younger than 12
years of age were discharged alive (100/100), as were breastfeeding
women (33/33). Due to a death of one pregnant woman, the survival
in that group was low, at 92.9% (13/14). The proportions of patients
discharged alive were similar for all other adults (97.3%–98.8%),
including for patients with history of previous HAT.
At the time of discharge from the treatment facility, clinical
characteristics had substantially improved (Karnofsky index, the
classification of patients performance as to their functional
impairment raised from mean 70% to 86%; neurological signs
decreased from 89% to 37%, bad general health state had reduced
from 80% to 14% and lymphadenopathy from 54% to 22%; the
patients who died during the treatment were excluded from this
analysis; data not shown).
Table 1. Baseline demographic, diagnostic and clinical characteristics of the patients, by centre.
Demographic characteristics All patients KASAI ORIENTAL province BANDUNDU province
Dipumba Katanda Ngandajika Bandundu Kwamouth Yasa Bonga
n (%) if not otherwise noted
Number of Patients treated 629 146 132 94 98 97 62
Children 0–4 years 35 (6%) 7 (5%) 7 (5%) 5 (5%) 5 (5%) 5 (5%) 6 (10%)
Children 5–11 years 65 (10%) 15 (10%) 22 (17%) 9 (10%) 4 (4%) 8 (8%) 7 (11%)
Adolescents/Adults .11 years 529 (84%) 124 (85%) 102 (77%) 80 (85%) 89 (91%) 84 (87%) 50 (81%)
Male/female ratio 1.3 1.8 1.2 2.0 0.9 0.9 1.1
Breastfeeding women 33 (5%) 9 (6%) 2 (2%) 2 (2%) 7 (7%) 9 (9%) 4 (6%)
Pregnant women 14 (2%) 1 (1%) 4 (3%) 1 (1%) 3 (3%) 2 (2%) 3 (5%)
Age, years, mean (SD)* 30 (16) 32 (16) 26 (15) 27 (14) 35 (18) 29 (16) 27 (18)
Weight, kg, mean (SD) 45 (16) 50 (17) 44 (17) 47 (18) 45 (14) 44 (14) 38 (16)
Malnutrition by age category
0–4 years: Weight for height .22SD 2 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%) 1 (1%)
5–14 years: Body-mass Index for age .22SD 14 (2%) 3 (2%) 4 (3%) 2 (2%) 1 (1%) 2 (2%) 2 (3%)
.14 years: Body-mass index ,18.5 kg/m2 172 (27%) 22 (15%) 19 (14%) 29 (31%) 39 (40%) 38 (39%) 25 (40%)
Previous HAT 135 (21%) 27 (18%) 51 (39%) 24 (26%) 12 (12%) 19 (20%) 2 (3%)
within 2 years of admission 84 (13%) 18 (12%) 27 (21%) 20 (21%) 8 (8%) 9 (9%) 2 (3%)
Parasitological findings
Presence of trypanosomes 558 (89%) 132 (90%) 128 (97%) 80 (85%) 85 (87%) 75 (77%) 58 (94%)
in lymph nodes 218 (35%) 53 (37%) 32 (24%) 44 (47%) 23 (23%) 40 (41%) 26 (42%)
in blood 162 (26%) 25 (17%) 32 (24%) 7 (8%) 44 (45%) 18 (19%) 36 (58%)
in CSF{ 341 (54%) 99 (68%) 86 (65%) 39 (42%) 49 (50%) 41 (42%) 27 (43%)
Leucocyte count in CSF, cells per ml, median 153 207 208 183 89 114 49
lower (25%) and upper (75%) quartiles 49; 345 96; 380 98; 442 85; 442 23; 250 25; 382 11; 172
.100 cells per ml 397 (63%) 108 (74%) 98 (74%) 66 (70%) 48 (49%) 53 (54%) 24 (39%)
Clinical characteristics
Karnofski index1, mean (SD) 70 (12) 65 (15) 67 (9) 68 (10) 74 (10) 70 (8) 80 (13)
Altered or bad general health state 502 (80%) 106 (73%) 108 (82%) 88 (94%) 69 (70%) 96 (99%) 35 (56%)
Lymphadenopathy 340 (54%) 73 (50%) 61 (46%) 62 (66%) 46 (47%) 69 (71%) 30 (48%)
Facial oedema 63 (10%) 11 (8%) 21 (16%) 22 (23%) 1 (1%) 4 (4%) 2 (3%)
Fever, axillary .37.5uC 38 (6%) 13 (9%) 4 (3%) 3 (3%) 10 (10%) 0 (0%) 8 (13%)
Sleeping disorders (insomnia, somnolence) 503 (80%) 126 (86%) 117 (89%) 83 (88%) 74 (76%) 60 (62%) 40 (64%)
Headache 472 (75%) 92 (63%) 115 (87%) 69 (73%) 72 (73%) 73 (75%) 49 (79%)
Asthenia 384 (61%) 107 (73%) 115 87%) 51 (54%) 69 (70%) 24 (25%) 20 (32%)
Fever history 371 (59%) 61 (42%) 111 (84%) 40 (43%) 63 (64%) 66 (68%) 30 (48%)
Pruritus 365 (58%) 102 (70%) 104 (79%) 45 (48%) 49 (50%) 41 (42%) 24 (39%)
Weight loss 346 (55%) 61 (42%) 103 (78%) 10 (11%) 73 (74%) 84 (87%) 13 (21%)
Tremor 277 (44%) 88 (60%) 82 (62%) 36 (38%) 44 (45%) 19 (20%) 5 (8%)
Walking disorder 258 (41%) 74 (51%) 86 (65%) 39 (41%) 49 (50%) 5 (5%) 4 (6%)
Behavioral disorder 208 (33%) 35 (24%) 74 (56%) 18 (19%) 36 (37%) 32 (33%) 16 (26%)
Convulsions 31 (5%) 10 (7%) 12 (9%) 2 (2%) 3 (3%) 4 (4%) 2 (3%)
doi:10.1371/journal.pntd.0001920.t001
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Treatment emergent adverse events were reported from the
first dose of study drug until discharge of the patient from the
treatment facility. Five hundred and seventy-eight patients (92%)
suffered from at least one adverse event and 79 patients (13%)
from at least one severe adverse event (CTCAE grades 3 to 5
including death cases). The overall safety profile and the nature
of the most frequently observed adverse events and severe
adverse events were similar for the study populations of interest,
with a few exceptions (Table 3). Pregnant women tended to be
affected more frequently by vomiting, asthenia and headache.
On the other hand, it was the only group not developing any
psychiatric disorder. Breastfeeding women showed double the
incidence of agitation than others (12%). Children had less
psychiatric events and reported less headaches, but had more
fever and injection site reactions. Anorexia was more frequently,
and fever less frequently reported in the population with previous
HAT.
6.5% of the patients received a repeated or added dose of
nifurtimox, often due to vomiting during the 30 minutes following
drug intake. This tended to occur more frequently in small
children (8.6%), pregnant (14.1%) and breastfeeding (9.1%)
women and patients with previous HAT (11.9%). One patient
ceased his NECT treatment due to recurrent convulsions
occurring just after 1 eflornithine administration, without having
had a known convulsion history. One patient had a temporary
nifurtimox interruption of 16 hours due to coma.
Thirty-two (5.1%) patients had a serious adverse event (SAE)
during hospitalisation. From those, 25 were considered as possibly
or probably related to study drug (Table 2). Thirteen patients had
an SAE affecting the nervous system including mood disorders,
psychosis, convulsions, ataxia and coma, while 8 patients had an
SAE that may have been induced by myelotoxicity, including
infections and anaemia (data not shown). All patients with an SAE
who did not die recovered without sequelae. No SAE was reported
for children of breastfeeding mothers during their hospitalisation
(Table 2).
During hospitalisation, 10 patients died of various causes
(infections, coma, anaemia, cardiogenic shock and non-specific
diagnosis). Three patients died during treatment, whilst 7 died
during the observation period. Eight of the 10 patients were
already in a bad health state prior to treatment, as reflected by
their Karnofsky Index at 60% or lower. Nine deaths were
considered to be possibly (7/9) or probably (2/9) related to NECT.
One death was considered unrelated.
Table 2. Treatment compliance, length of hospitalisation and in-hospitalisation safety of NECT by sub-population of interest.
Number of patients with All patients
Total Children Adolescents/adults Other female Previous HAT
0–4 years 5–11 years Male Female
Pregnant
women
Breastfeeding
women within 2 years
n (%) (N=629) (N=35) (N=65) (N=299) (N=183) (N=14) (N=33) (N=84)
Treatment and adherence
Treatment adherence
30 nifurtimox doses
received
590 (94%) 31 (89%) 63 (97%) 278 (93%) 177 (97%) 11 (79%) 30 (91%) 79 (94%)
14 eflornithine doses
received
621 (99%) 30 (86%) 65 (100%) 298 (100%) 182 (100%) 13 (93%) 33 (100%) 82 (98%)
Patients with
concomitant treatment
585 (94%) 30 (86%) 57 (88%) 281 (94%) 171 (93.4%) 14 (100%) 32 (97%) 76 (91%)
median concomitant
drugs per patient
4 4 4 4 5 6 4 5
Length of hospitalisation*
Median stay, in days 16 16 16 16 16 15.5 15 16
Range, in days 5–46 12–40 12–27 10–46 6–36 5–26 12–31 5–36
In-hospitalisation safety
Any adverse event 578 (92%) 31 (89%) 61 (94%) 273 (91%) 171 (93%) 14 (100%) 28 (85%) 77 (92%)
mean adverse events
per patient
4.2 2.7 3.4 4.3 4.5 5.7 4.2 4.5
Related adverse event{ 556 (88%) 30 (86%) 57 (88%) 264 (88%) 164 (90%) 14 (100%) 27 (82%) 71 (85%)
Severe adverse event{ 79 (13%) 4 (11%) 5 (8%) 38 (13%) 26 (14%) 3 (21%) 1 (3%) 12 (14%)
Serious adverse event 32 (5%) 1 (3%) 1 (2%) 16 (5%) 10 (6%) 1 (7%) 3 (9%) 5 (6%)
possibly or probably
related to treatment
25 (4%) 1 (3%) 0 12 (4%) 8 (4%) 1 (7%) 3 (9%) 4 (5%)
Death during hospitalisation 10 (1.6%) 0 0 4 (1.3%) 5 (2.7%) 1 (7%) 0 1 (1.2%)
Discharged alive 619 (98.4%) 35 100%) 65 (100%) 295 (98.7%) 178 (97.3%) 13 (92.9%) 33 (100%) 83 (98.8%)
HAT=Human African trypanosomiasis.
*Calculated from day of admission to day of discharge.
{Possibly or probably related to study drug.
{CTC grades 3–5.
doi:10.1371/journal.pntd.0001920.t002
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Discussion
Based on the results of randomised controlled trials [11,21] and
a case series [22], NECT is currently used as first-line treatment in
several African countries to treat 2nd stage T.b. gambiense HAT. To
better implement NECT in remote rural HAT treatment facilities,
the knowledge on the safety profile under such conditions must be
more extensively known. Here, we report the in-hospitalisation
safety of NECT obtained from 629 treated HAT patients in six
different treatment facilities in the DRC. Also, for the first time,
special populations, such as children below 15 years of age,
pregnant women and HAT relapses, were treated with NECT and
are described here. The effectiveness analysis will be available
once the 24 months follow-up of patients is completed in late 2012.
A matter of concern may be that similar dosages as for adults have
been administered to children below age 12, as in monotherapy
higher doses of nifurtimox and eflornithine are recommended for
children.
NECT in-hospitalisation safety in field conditions
Almost all - 98.4% (619/629) patients were discharged alive
after treatment. The nature, frequency and intensity of adverse
events were situated in the expected range as shown in previous
studies [11,21,22] and considering the fatal outcome of the disease.
NECT was sufficiently tolerated among all population sub-groups
in the context of 2nd stage HAT treatment. Most patients saw their
health improve during hospitalisation (Karnofsky index raise from
70% before treatment to 86% after treatment and general health
state improvement of 85% of the patients as judged by the
Investigators, data not shown). Concomitant treatments used to
manage adverse events and co-existing diseases were mainly
antiparasitic, antiinfective, analgesic, antipyretic, antiemetic drugs
and benzodiazepines.
Limitations
The evaluation of adverse events and causes of mortality was
complex, as symptoms were often related and confused with the
symptoms of the disease itself [23,24] or concomitant disease in a
background of severely ill and often malnourished patients. Apart
from nausea and vomiting, the symptoms observed during
NECT treatment are similar to HAT symptoms described
during anamnesis at enrolment and reported in the literature
[23]. A clear distinction of causality between the disease itself, the
co-morbidities and the study treatment is not possible in most
cases.
Similar in-hospital safety rates and profiles were observed
among the different population sub-groups including the small
children, pregnant (considering the low number in this group) or
breastfeeding women and patients having previously relapsed.
Implementing a clinical trial inevitably modifies field conditions,
as study procedures, patient’s safety recommendations, study
forms and external expertise are being brought to the centres.
Nevertheless, the study was carefully designed to minimise these
modifying effects, while maintaining adequate quality standards.
The facilities’ hospitalisation conditions were maintained: for
example food was not systematically provided, unless a patient was
suffering from advanced malnutrition; concomitant medication
was based on routine stock of drugs. However, for safety reasons,
emergency kits containing drugs for treatment of potentially severe
or life threatening events were provided to the centres before the
inclusion of the first patient. The study was implemented in six
treatment facilities in the DRC under conditions mimicking field
reality as much as possible.
Comparison to previous studies and generalisability
The demographic characteristics of patient populations varied
slightly between facilities, but nonetheless reflected the observed
distribution of the HAT populations described in the literature
[4,13] and therefore allows comparison with previous studies even
if here additional groups have been added with similar baseline
and in-hospitalisation safety profiles.
The proportion of patients discharged alive after NECT
treatment in field conditions was comparable to eflornithine
monotherapy and to previous NECT trials in field conditions,
varying from 94.1% to 99.3%, depending on the drug in use
[4,11,13,14,21,22]. The fatality rate during hospitalisation did not
exceed the projected values derived from literature and field
reports (0.8–2.1%; [4,11,13,14]).
The median length of hospitalisation for a patient was 16 days
including premedication and observation period compared to 25–
30 days for melarsoprol [3] or 20 days for eflornithine
monotherapy (personal communication PNLTHA DRC). The
NECT therapy could be accomplished in 10 days for most
patients. Its dosage schedule is simpler to apply than eflornithine
monotherapy (56 versus 14 intravenous infusions [4]), requiring
less nursing staff.
Compared to the formerly used standard HAT treatments,
NECT is safer than melarsoprol (2.7–34% melarsoprol case
fatality rate [3,4]) and similar to eflornithine monotherapy.
The overall safety profile of NECT in the present study is
similar to the safety data of NECT obtained during previous
studies comparing different drug combinations [21], Nifurtimox-
Eflornithine case series [22] and the NECT phase III RCT
comparing NECT to eflornithine monotherapy [11]. In this study,
arrhythmias, musculoskeletal and connective tissue disorders,
injection site reactions and headaches were reported less
frequently compared to the NECT phase III RCT [11]. All other
adverse events were similar in nature, intensity and frequency.
These differences in adverse event reporting can be explained by
the different design and context of both studies. Another limitation
of the comparability is that adverse events reported during
previous studies were coded according to different standard
dictionaries (i.e. the CTC).
Potentially harmful neurological adverse events, such as
convulsions (9%) and coma (1%) compatible with an encephalo-
pathic syndrome were observed in 13 SAE cases (2.1%). However,
as convulsions already occurred in 31 patients (5%) prior to
treatment (Table 1), it is difficult to assess if they were caused by
the disease, were related to the treatment regimen or resulted from
a combination of both. These cases of encephalopathic-like
reactions are not directly comparable to previous eflornithine
[4,13,14] or melarsoprol [3,25,26] trials, as the same definition of
the encephalopathic syndrome [25,27] was not consistently used in
all those trials.
Switching from a controlled environment, such as during the
NECT phase III RCT where patients were closely followed [11] to
field conditions raised some concerns about infection risk at the
injection site and infections in general. However, during the
present trial, no evidence of increased infection was observed.
As already expressed by Priotto [11], vomiting remains a
concern because of its frequency, especially during the first days of
NECT therapy. Nifurtimox doses were repeated once or twice in
6.5% of the patients. The final effectiveness analysis will enable
evaluation of the impact of vomiting on the cure rate. A close
observation of nausea and vomiting is recommended in order to
allow the timely administration of a second nifurtimox dose if
necessary, as well as the prescription of an anti-emetic drug.
NECT for HAT Implemented in Field Conditions
PLOS Neglected Tropical Diseases | www.plosntds.org 9 November 2012 | Volume 6 | Issue 11 | e1920
Conclusions and recommendations
The in-hospital safety and feasibility of NECT in field
conditions have been shown to be satisfactory in this trial.
Consequently, its use in remote, rural sleeping sickness treatment
facilities in endemic countries seems justified. In field conditions
and in a wider population, including children, the use of NECT
displayed a similar tolerability profile to that previously described
in more stringent clinical trial conditions [11]. However, wide
implementation of NECT demands sufficient levels of human
resources for IV infusion treatment and that financial and
logistical barriers in the supply chain management are overcome.
In addition, a common international, standardised pharmacov-
igilance system should be supported to further improve the
collection of safety and efficacy data in specific populations
(pregnant/breastfeeding women and children) and to monitor the
emergence of rare severe adverse events.
The in-hospital evolution of patients was similar to previously
published NECT results. The effectiveness will be assessed at the
end of the 24 months follow-up period.
Acknowledgments
We thank the patients and their families for their participation, as well as
the medical and support staff of the PNLTHA and BDOM/KIKWIT for
their hard work in caring for patients. The authors thank the work of the
provincial heads and directorate of the PNLTHA and the BDOM who
permitted the conduct of the study (Drs Claude Sese, Crispin Lumbala,
Florent Mbo, van Kumpel and Cecile van Geerts). The World Health
Organisation (WHO) Geneva and Kinshasa provided the drugs for free
and supported the logistics (Drs. Pere Simarro, Jose Ramon Franco and
Carmelo Santercole). Logistic support was also received from Doctors
Without Borders (MSF) logistic centre in Bordeaux, France and the DNDi
local office in Kinshasa (Mr Richard Mvumbi). The HAT Platform in
Kinshasa (Dr Augustin Ebeja) provided liaison with the local ethics
committee. The Swiss Tropical and Public Health Institute, Basel and
Kinshasa supported the implementation and monitoring of the study (Drs.
Sonja Bernhard, Gabriele Pohlig, Christian Burri, Didier Kalemwa and
Mr Jean-Bosco Inyamweni). Training was given by Drs. Jorge Seixas
(Institute of Hygiene and Tropical Medicine IHMT Lisbon, Portugal),
Serge Kazadi (Doctors Without Borders, MSF Switzerland) and the
medical staff of the PNLTHA Kasai Oriental (Dr Medard Ilunga, Jeremy
Ilunga and Patrice Kabangu). Scientific advice was received from Drs. Els
Torreele, Francois Chappuis, Marc Gastellu, Abiy Tamrat, Nathalie Strub,
Gerardo Priotto and Christian Burri. We also thank the Data Safety and
Monitoring Board (DSMB, Drs. Dominique Legros, Bruno Scherrer and
Pascal Lutumba). Data management was provided by RCTs, Lyon, France
and pharmacovigilance reporting by EP consultants, Paris, France.
Author Contributions
Conceived and designed the experiments: CS AK SG VKWM. Performed
the experiments: WM MI IL SM PN DT NM MK. Analyzed the data: CS
AK JB SG SB OVM. Wrote the paper: CS AK SG OVM.
References
1. WHO (2011) Neglected Tropical Diseases. Available: http://www.who.int/
trypanosomiasis_african/en/. Accessed 2012 Feb 20.
2. Simarro PP, Cecchi G, Paone M, Franco JR, Diarra A, et al. (2010) The Atlas of
human African trypanosomiasis: a contribution to global mapping of neglected
tropical diseases. Int J Health Geogr 9: 57.
3. Schmid C, Richer M, Bilenge CM, Josenando T, Chappuis F, et al. (2005)
Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage
human African trypanosomiasis: Confirmation from a multinational study
(Impamel II). Journal of Infectious Diseases 191: 1922–1931.
4. Balasegaram M, Young H, Chappuis F, Priotto G, Raguenaud ME, et al. (2009)
Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense
sleeping sickness in nine Medecins Sans Frontieres programmes. Trans R Soc
Trop Med Hyg 103: 280–290.
5. Dahl B (2011) From sentinel surveillance for sleeping sickness treatment failure
to the development of a pharmacovigilance approach [PhD thesis]. Basel:
University of Basel. 149 p.
6. Robays J, Nyamowala G, Sese C, Betu Ku Mesu Kande V, Lutumba P, et al.
(2008) High failure rates of melarsoprol for sleeping sickness, Democratic
Republic of Congo. Emerg Infect Dis 14: 966–967.
7. Pepin J, Mpia B (2005) Trypanosomiasis relapse after melarsoprol therapy,
Democratic Republic of Congo, 1982–2001. Emerg Infect Dis 11: 921–927.
8. Matovu E, Enyaru JC, Legros D, Schmid C, Seebeck T, et al. (2001)
Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
Trop Med Int Health 6: 407–411.
9. Stanghellini A, Josenando T (2001) The situation of sleeping sickness in Angola:
a calamity. Tropical Medicine and International Health 6: 330–334.
10. WHO (2010) WHO Model List of Essential Medicines Available: http://www.
who.int/medicines/publications/essentialmedicines/Updated_sixteenth_adult_
list_en.pdf. Accessed 2012 Feb 20.
11. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009)
Nifurtimox-eflornithine combination therapy for second-stage African Trypano-
soma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III,
non-inferiority trial. Lancet 374: 56–64.
12. Program CTE (2006) Common Terminology Criteria for Adverse Events,
Version 3.0 Available: http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/docs/ctcaev3.pdf. Accessed 2012 Feb 20.
13. Chappuis F, Udayraj N, Stietenroth K, Meussen A, Bovier PA (2005)
Eflornithine is safer than melarsoprol for the treatment of second-stage
Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect
Dis 41: 748–751.
14. Priotto G, Pinoges L, Fursa IB, Burke B, Nicolay N, et al. (2008) Safety and
effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping
sickness in Sudan: cohort study. BMJ 336: 705–708.
15. Fleiss JL, Levin B, Paik MC (2003) Statistical Methods for Rates and
Proportions. New York: John Wiley & Sons.
16. NCSS (2008) PASS 2008 (http://www.ncss.com/download_PASS11.html)
accessed (20.02.2012).
17. MEDRA (2010) Medical Dictionary for regulatory activities - Maintenance and
Service Support Organisation. Available: http://www.meddramsso.com/index.
asp. Accessed 2012 Feb 20.
18. WHO (2006) ATC/DDD Index (http://www.whocc.no/atc_ddd_index/)
accessed (20.02.2012)
19. WHO (1995) Physical status: The use and interpretation of anthropometry
(http://whqlibdoc.who.int/trs/WHO_TRS_854.pdf) Accessed 2012 Feb 20.
20. WHO (2007) Growth reference data for 5–19 years. Available: http://www.
who.int/growthref/en/. Accessed 2012 Feb 20.
21. Priotto G, Fogg C, Balasegaram M, Erphas O, Louga A, et al. (2006) Three drug
combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a
randomized clinical trial in Uganda. PLoS Clin Trials 1: e39.
22. Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, et al. (2007) Nifurtimox
plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series.
PLoS Negl Trop Dis 1: e64.
23. Blum J, Schmid C, Burri C (2006) Clinical aspects of 2541 patients with second
stage human African trypanosomiasis. Acta Trop 97: 55–64.
24. Blum JA, Schmid C, Burri C, Hatz C, Olson C, et al. (2009) Cardiac Alterations
in Human African Trypanosomiasis (T.b. gambiense) with Respect to the
Disease Stage and Antiparasitic Treatment. PLoS Negl Trop Dis 3: e383.
25. Blum J, Nkunku S, Burri C (2001) Clinical description of encephalopathic
syndromes and risk factors for their occurrence and outcome during melarsoprol
treatment of human African trypanosomiasis. Trop Med Int Health 6: 390–400.
26. Burri C, Nkunku S, Merolle A, Smith T, Blum J, et al. (2000) Efficacy of new,
concise schedule for melarsoprol in treatment of sleeping sickness caused by
Trypanosoma brucei gambiense: a randomised trial. Lancet 355: 1419–1425.
27. Seixas J (2005) Investigations on the encephalopathic syndrome during
melarsoprol treatment of human african trypanosomiasis [PhD]. Lisboa:
Universidade Nova de Lisboa. 250 p.
NECT for HAT Implemented in Field Conditions
PLOS Neglected Tropical Diseases | www.plosntds.org 10 November 2012 | Volume 6 | Issue 11 | e1920
